RxDoctor Payments Data

Conor Tibbs, PA

Physician Assistant · Carlsbad, CANPI 1275257776

Payments from drug & device makers

$2,295in general payments, 2019–2025

Across 65 payments — averaging $35.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$712
  • SPR Therapeutics, Inc$511
  • Averitas Pharma Inc.$217
  • Vertos Medical, Inc.$110
  • Nalu Medical, Inc.$107
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$103
  • plus $535 from 11 others

What the payments were for

  • Travel & lodging$2169%
  • Food & beverage$2,07991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,295 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$18,766
Medicare patients
24
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl95$59,146
NucyntaTapentadol Hcl19$18,864
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen675$18,230
Nucynta ErTapentadol Hcl27$18,058
Oxycodone Hcl687$17,285
Xtampza ErOxycodone Myristate31$16,604
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen326$13,238
Buprenorphine47$10,681
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl77$9,806
Morphine Sulfate ErMorphine Sulfate299$7,691
Fentanyl73$6,215
Naloxone Hcl73$4,227
Hydromorphone Hcl161$3,240
Gabapentin224$3,192
Pregabalin120$3,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Nucynta Er, Xtampza Er$79$53,52777 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →